

A strategy for SARS-CoV-2 vaccination in Yemen

Yemen has one of the most fragile health-care systems and is currently experiencing war and famine. Since 2015, the country's humanitarian crisis has resulted in the emergence and re-emergence of debilitating infectious diseases and severely weakened the country's health infrastructure.

The first COVID-19 case in Yemen was reported in April, 2020, and WHO warned of a possible catastrophic explosion of cases.¹ Early epidemiological data showed a high mortality rate in individuals younger than 60 years.² In the absence of well equipped laboratories, infrastructure, and testing tools, misdiagnoses and underestimation of new cases have resulted in inconsistencies in reported case numbers. Indeed, a recent geospatial analysis of burial activity in the Aden governorate³ during the pandemic suggested a substantial, under-ascertained impact of COVID-19, implying that reported mortality data are inaccurate.

According to the latest WHO Yemen Situation Report for March, 2021,⁴ Yemen has received 360 000 doses of AstraZeneca COVID-19 vaccines through the COVAX initiative. Yemen is expecting to receive 14 million doses of COVID-19 vaccines through the COVAX, enough to vaccinate about 23% of the population.⁵ According to OurWorldInData COVID-19 vaccinations dashboard, as of May 29, 2021, just over 104 000 people have received at least one dose of COVID-19 vaccine.

All things considered, it is important to fashion out a safe model for vaccination rollout in Yemen, a country without a system for tracking virus spread in its susceptible community.

Worthy of note is the fact that just less than 3% of the Yemeni population is older than 65 years, which is relatively small proportion of the population compared with many other

countries, and so the number of doses of vaccine supplied will be sufficient to fully vaccinate older people. A vaccination strategy based on logistical considerations should be structured for the other priority and risk groups in the Yemeni population to ensure adequate, equitable, and effective vaccination. As a medical product, vaccines should meet postmarketing surveillance requirements, which implies drug tracking and monitoring. Similar practice is applied after sale of pharmaceutical drugs, medical devices, and medical products.

Therefore, besides the meritocratic prioritisation strategy and global equity initiative adopted by different countries, the serological tracking system should be simultaneously considered. Firstly, we suggest that everyone in the target age group or eligible for the vaccine should undergo SARS-CoV-2 testing before the vaccine is administered. Secondly, the serological tracing of people who are infected should be done, whether the vaccine recipient possesses antibodies should be reported, and also the concentration of antibodies should be measured. Data from several studies suggest that one dose of vaccine is enough for an individual who was previously infected, and taking this into account could prevent vaccine shortage and ensure wider vaccination coverage.^{6,7}

Finally, the quality of the serological testing is very important and ought to be thoroughly regulated. Serological testing should be quantitative by determining optical density and the cutoff with the binding index thus ensuring measurement of numerical values for the proportion of antibodies in the blood. The serological tracking system must have been tested for cross-reactivity and interfering substances that might affect the interpretation of results. The integration and implementation (diagnostic aspect and vaccine matching) strategy should be supervised and adopted by the ministry of health and other local authorities.

We declare no competing interests.

Abdullah Nasser, *Fathiah Zakham
fathiah_zakham@yahoo.com

Scientific Research and Development Department, MEDIPAN, Berlin, Germany (AN); Scientific Research and Development Department, GA Generic Assays, Berlin, Germany (AN); Faculty of Medicine and Health Sciences, Hodeidah University, Hodeidah, Yemen (FZ); Department of Virology, Faculty of Medicine, Department of Veterinary Biosciences, Faculty of Veterinary Medicine, and Faculty of Pharmacy, University of Helsinki, Helsinki 00014, Finland (FZ)

- Ghobari M. War-ravaged Yemen confirms first coronavirus case, braces for more. April 10, 2020. <https://www.reuters.com/article/us-health-coronavirus-yemen-case/war-ravaged-yemen-confirms-first-coronavirus-case-braces-for-more-idUSKCN21S0EI> (accessed June 3, 2021).
- Al-Waleedi AA, Naieni JD, Thabet AAK, et al. The first 2 months of the SARS-CoV-2 epidemic in Yemen: analysis of the surveillance data. *PLoS One* 2020; **15**: e0241260.
- Koum Besson ES, Norris A, Bin Ghouth AS, et al. Excess mortality during the COVID-19 pandemic: a geospatial and statistical analysis in Aden governorate, Yemen. *BMJ Global Health* 2021; **6**: e004564.
- WHO. WHO Yemen Update Situation report - Issue no.3 (March 2021). May 9, 2021. <https://reliefweb.int/report/yemen/who-yemen-update-situation-report-issue-no3-march-2021> (accessed June 3, 2021).
- UN Office for the Coordination of Humanitarian Affairs. Yemen humanitarian response plan aims to avert famine, prevent disease outbreaks and protect civilians. March, 2021. https://reliefweb.int/sites/reliefweb.int/files/resources/Yemen_Humanitarian_Update_2021_No_3.pdf (accessed June 3, 2021).
- Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet* 2021; **397**: 1178–81.
- Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet* 2021; **397**: 1057–58.



Alhmad Al-Basha/Getty Images

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates

Merryn Voysey and colleagues¹ provide some of the first evidence of the effectiveness of ChAdOx1 nCoV-19 vaccine (AZD1222) against asymptomatic infections. However, readers might be surprised by the non-intuitive results reported in the tables, where vaccine efficacy estimates for asymptomatic infections are close to the null or even negative.

Voysey and colleagues¹ suggest that protection against asymptomatic



For the COVID-19 vaccinations dashboard see <https://ourworldindata.org/covid-vaccinations>

Submissions should be made via our electronic submission system at <http://ees.elsevier.com/thelancet/>

infections is shown by the outcome that includes any nucleic acid amplification test-positive cases. However, there is still value in directly estimating the efficacy against asymptomatic infections. As estimated in table 1 of the Article,¹ this parameter is calculated using the rate ratio that compares asymptomatic infections between the vaccinated and control groups. However, we argue that the rate of asymptomatic infections in the control group is not the appropriate comparator because it requires the implausible assumption that all prevented symptomatic cases were completely averted, rather than converted to asymptomatic infections. If it is instead assumed that all symptomatic infections prevented by the vaccine would become asymptomatic, the appropriate counterfactual would be the rate of asymptomatic infections in the control group plus the rate of symptomatic cases that was averted by vaccine.

Using data presented in table 1 of the Article,¹ we calculated expected efficacy on the basis of this alternative counterfactual comparison to estimate an upper bound on the true efficacy against asymptomatic infections. We estimate efficacy against asymptomatic COVID-19 cases to be 61.9% (appendix), which is much higher than the reported estimate of 22.2%. This analysis provides further confidence that the ChAdOx1 nCoV-19 vaccine (AZD1222) provides substantial protection against asymptomatic infections.

ETRM reports grants from the US National Institute of Allergy and Infectious Diseases. JAP-M declares no competing interests.

*Elizabeth T Rogawski McQuade,
James A Platts-Mills
etr5m@virginia.edu

Department of Public Health Sciences (ETRM) and Division of Infectious Diseases and International Health (ETRM, JAP-M), University of Virginia, Charlottesville, VA 22908, USA

1 Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; **397**: 881–91.

Authors' reply

It is well established that randomised controlled trials are the gold standard for estimating the effect of interventions. In such studies, outcomes in participants randomised to receive the new intervention are compared with those randomised to the control product, to produce unbiased estimates of the effect of the intervention.

Elizabeth McQuade and James Platts-Mills show a new analysis of published data from our randomised controlled trial¹ of the ChAdOx1 nCoV-19 (AZD1222) vaccine to further explore the effect of vaccination on prevention of asymptomatic infections. McQuade and Platts-Mills propose a counterfactual that is the combination of symptomatic cases prevented and asymptomatic cases observed, to represent the hypothetical situation that might occur if a vaccine solely had effect on symptomatic infections and had no ability to prevent asymptomatic infection. In this situation, an excess of asymptomatic cases in the vaccine group would be observed, which McQuade and Platts-Mills attempt to quantify.

Although the underlying assumptions might be too stringent to be realistic, the results they showed are interesting and highlight the difficulties of estimating true vaccine efficacy against asymptomatic infections. We showed efficacy against all cases—that is, the combination of symptomatic or asymptomatic cases.¹ The analysis of any nucleic acid amplification test-positive outcomes maintains the benefits of the randomisation within the trial while incorporating the people that might have otherwise been symptomatic were it not for vaccination. The highly significant efficacy seen for this endpoint shows the overall benefit of the vaccine in preventing opportunity for transmission of SARS-CoV-2.¹

Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. AJP is Chair of the UK Department of Health and Social Care's Joint Committee on Vaccination & Immunisation, but does not participate in discussions on COVID-19 vaccines, is a member of WHO's Strategic Advisory Group of Experts, and a UK National Institute for Health Research (NIHR) Senior Investigator. MV declares no competing interests. This research is funded by NIHR, UK Research and Innovation, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, and the South African Medical Research Council. We are grateful to the NIHR infrastructure provided through the NIHR Biomedical Research Centres and the NIHR Clinical Research Network at the UK study sites. The views expressed in this Correspondence are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Merryn Voysey, *Andrew J Pollard
andrew.pollard@paediatrics.ox.ac.uk

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK

1 Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* 2021; **397**: 881–91.

COVID-19 vaccine efficacy data: solid enough to delay second dose?

Sharon Amit and colleagues¹ suggest that after a first dose of BNT162b2 vaccine, there was an adjusted rate reduction of COVID-19 disease of 85% (71–92) for days 15–28 in vaccinated compared with unvaccinated health-care workers (HCWs).¹ We think this Correspondence has fundamental flaws and address them here.

First, HCWs have been shown to have higher risks for SARS-CoV-2 viral infection, which result in asymptomatic, pre-symptomatic (at time of study initiation), or symptomatic infection.^{2,3}

Second, individuals documented to have had a SARS-CoV-2 viral infection have a substantially greater response to the first dose of vaccine (up to over a thousand times the neutralising antibodies before the first vaccine dose), which is much greater than the

See Online for appendix